person · Reporting owner

Leonard Braden Michael

Disclosed activity across 17 companies

Tapewire entity: 46438
SEC CIK: 0001373603

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BUILD-A-BEAR WORKSHOP INCBBW · Entity 5717	Former Director of the Issuer	September 28, 2017	October 02, 2017
Cyteir Therapeutics, Inc.CYT · Entity 92707	10% owner	March 20, 2024	March 25, 2024
Disc Medicine, Inc.GMTX · Entity 2273	10% owner	October 26, 2022	October 27, 2022
Enliven Therapeutics, Inc.IMRA · Entity 4024	10% owner	January 03, 2023	January 06, 2023
Metacrine, Inc.MTCR · Entity 115177	10% owner	December 19, 2022	December 21, 2022
OnKure Therapeutics, Inc.OKUR · Entity 6550	Former 10% owner of RPHM	October 07, 2024	October 09, 2024
Orchids Paper Products CO /DETISUQ · Entity 158423	10% owner	April 03, 2019	April 10, 2019
Outset Medical, Inc.OM · Entity 7026	10% owner	October 01, 2026	October 05, 2026
ProPhase Labs, Inc.PRPH · Entity 8699	10% owner	September 29, 2017	October 02, 2017
RETRACTABLE TECHNOLOGIES INCRVP · Entity 7624	10% owner	December 29, 2022	December 29, 2022
Satsuma Pharmaceuticals, Inc.STSA · Entity 112442	10% owner	November 21, 2022	November 23, 2022
Talis Biomedical CorpTLIS · Entity 87664	10% owner	September 05, 2024	September 09, 2024
Tectonic Therapeutic, Inc.TECX · Entity 5328	Former 10% owner of AVROBIO	June 20, 2024	June 25, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BUILD-A-BEAR WORKSHOP INC

Report date September 28, 2017 · Filed October 02, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	1,281,000	Last balance in matching sequence After 2017-09-29 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-09-28 · Sale · Disposed 25,000 · Balance 1,283,000 F1: Represents the sale of shares in multiple transactions, ranging in price from $9.20 to $9.25, resulting in a weighted average sale price per share of $9.2056. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F3: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2017-09-29 · Sale · Disposed 2,000 · Balance 1,281,000 F2: Represents the sale of shares in multiple transactions, at 9.20, resulting in a weighted average sale price per share of $9.20. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F3: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	142,043	Reported balance Holding disclosure · report date 2017-09-28 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 142,043

Filing footnotes · ownership attribution and instrument terms

F1: Represents the sale of shares in multiple transactions, ranging in price from $9.20 to $9.25, resulting in a weighted average sale price per share of $9.2056. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.

F2: Represents the sale of shares in multiple transactions, at 9.20, resulting in a weighted average sale price per share of $9.20. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.

F3: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Cyteir Therapeutics, Inc.

Report date March 20, 2024 · Filed March 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P	3,654,053	Reported balance After 2024-03-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-03-20 · Purchase · Acquired 170,589 · Balance 3,654,053 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	335,000	Reported balance Holding disclosure · report date 2024-03-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 335,000

Filing footnotes · ownership attribution and instrument terms

F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote

Disc Medicine, Inc.

Report date October 26, 2022 · Filed October 27, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	247,500	Reported balance After 2022-10-26 transaction · row 1 1 source row Row 1 · 2022-10-26 · Sale · Disposed 22,500 · Balance 247,500 F2: The shares were sold in multiple transactions at $2.09.
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	5,000,000	Reported balance Holding disclosure · report date 2022-10-26 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 5,000,000 F1: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F2: The shares were sold in multiple transactions at $2.09.

Enliven Therapeutics, Inc.

Report date January 03, 2023 · Filed January 06, 2023 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	1,767,774	Reported balance After 2023-01-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-01-03 · Sale · Disposed 1,250,000 · Balance 1,767,774 F2: This form was filed to correct the transaction date to 1/3/2023. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	230,000	Reported balance Holding disclosure · report date 2023-01-03 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance 230,000

Filing footnotes · ownership attribution and instrument terms

F2: This form was filed to correct the transaction date to 1/3/2023.

Metacrine, Inc.

Report date December 19, 2022 · Filed December 21, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	6,160,570	Last balance in matching sequence After 2022-12-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2022-12-19 · Purchase · Acquired 101,384 · Balance 5,990,349 F2: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2022-12-20 · Purchase · Acquired 50,122 · Balance 6,040,471 F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 3 · 2022-12-21 · Purchase · Acquired 120,099 · Balance 6,160,570 F4: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	600,000	Reported balance Holding disclosure · report date 2022-12-19 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 600,000

Filing footnotes · ownership attribution and instrument terms

F2: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F4: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.

OnKure Therapeutics, Inc.

Report date October 07, 2024 · Filed October 09, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHoldings of BML Investment Partners, L.P.	345,739	Reported balance After 2024-10-07 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-10-07 · Other · Acquired 345,739 · Balance 345,739 F1: Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	102,076	Reported balance After 2024-10-07 transaction · row 2 1 source row Row 2 · 2024-10-07 · Other · Acquired 102,076 · Balance 102,076 F3: Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").

Filing footnotes · ownership attribution and instrument terms

F1: Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").

F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F3: Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").

Orchids Paper Products CO /DE

Report date April 03, 2019 · Filed April 10, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	1,329,963	Reported balance Holding disclosure · report date 2019-04-03 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,329,963 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	128,000	Reported balance Holding disclosure · report date 2019-04-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 128,000

Filing footnotes · ownership attribution and instrument terms

Outset Medical, Inc.

Report date October 01, 2026 · Filed October 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHoldings of BML Investment Partners, L.P.	2,764,610	Last balance in matching sequence After 2026-10-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-10-01 · Purchase · Acquired 228,334 · Balance 2,748,035 F2: The shares were purchased in multiple transactions between $2.90 and $3.85 with an average price of $3.53. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2026-10-02 · Purchase · Acquired 16,575 · Balance 2,764,610 F3: The shares were purchased in multiple transactions at an average price of $3.8758 per share. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F2: The shares were purchased in multiple transactions between $2.90 and $3.85 with an average price of $3.53.

F3: The shares were purchased in multiple transactions at an average price of $3.8758 per share.

ProPhase Labs, Inc.

Report date September 29, 2017 · Filed October 02, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	627,322	Reported balance After 2017-09-29 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-09-29 · Sale · Disposed 1,695,305 · Balance 627,322 F1: 1. These shares were sold to the Issuer through the tender offer by the Issuer for 4,000,000 shares of its common stock. F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: 1. These shares were sold to the Issuer through the tender offer by the Issuer for 4,000,000 shares of its common stock.

RETRACTABLE TECHNOLOGIES INC

Report date December 29, 2022 · Filed December 29, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	688,575	Reported balance After 2022-12-29 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-12-29 · Sale · Disposed 3,000,000 · Balance 688,575 F2: The shares were sold in one negotiated transaction at $1.60. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	387,500	Reported balance Holding disclosure · report date 2022-12-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 387,500

Filing footnotes · ownership attribution and instrument terms

F2: The shares were sold in one negotiated transaction at $1.60.

Satsuma Pharmaceuticals, Inc.

Report date November 21, 2022 · Filed November 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	150,000	Reported balance After 2022-11-21 transaction · row 1 1 source row Row 1 · 2022-11-21 · Purchase · Acquired 150,000 · Balance 150,000 F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.70 to $0.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	6,440,000	Reported balance Holding disclosure · report date 2022-11-21 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 6,440,000 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein

Filing footnotes · ownership attribution and instrument terms

F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.70 to $0.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

Talis Biomedical Corp

Report date September 05, 2024 · Filed September 09, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	248,702	Last balance in matching sequence After 2024-09-06 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2024-09-05 · Purchase · Acquired 5,100 · Balance 223,702 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2024-09-06 · Purchase · Acquired 25,000 · Balance 248,702 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

Tectonic Therapeutic, Inc.

Report date June 20, 2024 · Filed June 25, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P,	400,355	Reported balance After 2024-06-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-06-20 · Other · Acquired 400,355 · Balance 400,355 F1: Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	33,333	Reported balance After 2024-06-20 transaction · row 2 1 source row Row 2 · 2024-06-20 · Other · Acquired 33,333 · Balance 33,333 F3: Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.

F3: Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AN2 Therapeutics, Inc.

Report date June 12, 2025 · Filed June 16, 2025

Section 16 reporting ended · disclosed 2025-06-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHolding of BML Investment Partners, L.P.	3,017,432	Reported balance After 2025-05-28 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-05-28 · Sale · Disposed 200,000 · Balance 3,017,432 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

ASTROTECH Corp

Report date October 03, 2025 · Filed October 08, 2025

Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHoldings of BML Investment Partners, L.P	0	Reported balance After 2025-10-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-10-03 · Sale · Disposed 220,410 · Balance 0 F2: The shares were sold in multiple transactions at an average price of $7.1305. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-10-03 transaction · row 2 1 source row Row 2 · 2025-10-03 · Sale · Disposed 9,166 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F2: The shares were sold in multiple transactions at an average price of $7.1305.

Aclaris Therapeutics, Inc.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHoldings of BML Investment Partners, L.P.	13,950,000	Reported balance After 2026-04-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-04-23 · Sale · Disposed 300,000 · Balance 13,950,000 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

Adverum Biotechnologies, Inc.

Report date December 04, 2025 · Filed December 05, 2025

Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHoldings of BML Investment Partners, L.P.	1,958,080	Reported balance After 2025-12-04 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-12-04 · Sale · Disposed 524,560 · Balance 1,958,080 F2: Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	191,800	Reported balance Holding disclosure · report date 2025-12-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 191,800

Filing footnotes · ownership attribution and instrument terms

F2: Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 02, 2026 Filed Oct 5, 2026 23:24 UTC	Outset Medical, Inc. OM · Entity 7026	PurchaseCommon Stock	16,575	$3.88	$64,241.39	Disclosure SEC source: 0001373604-26-000050 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 2,764,610 F3 · price: The shares were purchased in multiple transactions at an average price of $3.8758 per share. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 01, 2026 Filed Oct 5, 2026 23:24 UTC	Outset Medical, Inc. OM · Entity 7026	PurchaseCommon Stock	228,334	$3.53	$806,019.02	Disclosure SEC source: 0001373604-26-000050 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 2,748,035 F2 · price: The shares were purchased in multiple transactions between $2.90 and $3.85 with an average price of $3.53. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 15, 2026 Filed May 18, 2026 13:53 UTC	Outset Medical, Inc. OM · Entity 7026	OtherCommon Stock	323,000	$5.00	$1,615,000.00	Disclosure SEC source: 0001373604-26-000043 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 2,519,701 F2 · kind: The reporting owner was short June, 2026 put options and these shares were assigned on expiration. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 11, 2026 Filed May 12, 2026 20:34 UTC	Outset Medical, Inc. OM · Entity 7026	OtherCommon Stock	96,900	$5.00	$484,500.00	Disclosure SEC source: 0001373604-26-000036 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 2,196,701 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 08, 2026 Filed May 12, 2026 20:34 UTC	Outset Medical, Inc. OM · Entity 7026	OtherCommon Stock	197,600	$5.00	$988,000.00	Disclosure SEC source: 0001373604-26-000036 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 2,099,801 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
April 23, 2026 Filed Apr 27, 2026 23:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	300,000	$4.53	$1,359,000.00	Disclosure SEC source: 0001373604-26-000034 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 13,950,000 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
December 04, 2025 Filed Dec 5, 2025 23:20 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	SaleCommon Stock	524,560	$4.19	$2,200,371.83	Disclosure SEC source: 0001373604-25-000122 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 1,958,080 F2 · price: Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
December 03, 2025 Filed Dec 4, 2025 02:39 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	SaleCommon Stock	222,925	$4.17	$929,597.25	Disclosure SEC source: 0001373604-25-000118 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P Disclosed balance after: 2,428,640 F4 · price: Represents shares sold in multiple transactions at a price of $4.17 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
December 02, 2025 Filed Dec 4, 2025 02:39 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	SaleCommon Stock	51,961	$4.20	$218,236.20	Disclosure SEC source: 0001373604-25-000118 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P Disclosed balance after: 2,705,565 F3 · price: Represents shares sold in multiple transactions at a price of $4.20 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
December 01, 2025 Filed Dec 4, 2025 02:39 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	SaleCommon Stock	300,000	$4.20	$1,260,000.00	Disclosure SEC source: 0001373604-25-000118 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P Disclosed balance after: 2,757,526 F2 · price: Represents shares sold in multiple transactions at a price of $4.20 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 03, 2025 Filed Oct 8, 2025 00:51 UTC	ASTROTECH Corp ASTC · Entity 7805	SaleCommon Stock	9,166	$5.83	$53,437.78	Disclosure SEC source: 0001373604-25-000106 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document
October 03, 2025 Filed Oct 8, 2025 00:51 UTC	ASTROTECH Corp ASTC · Entity 7805	SaleCommon Stock	220,410	$7.13	$1,571,633.51	Disclosure SEC source: 0001373604-25-000106 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P Disclosed balance after: 0 F2 · price: The shares were sold in multiple transactions at an average price of $7.1305. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 30, 2025 Filed May 30, 2025 21:40 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	SaleCommon Stock	7,000	$1.03	$7,226.80	Disclosure SEC source: 0001373604-25-000084 · form4.xml · nonDerivative · entry 4 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,217,432 F2 · price: The shares were sold in multiple transactions at an average price of $1.0324. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 30, 2025 Filed May 30, 2025 21:40 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	SaleCommon Stock	425,000	$1.01	$429,250.00	Disclosure SEC source: 0001373604-25-000084 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,224,432 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 28, 2025 Filed May 30, 2025 21:40 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	SaleCommon Stock	100,000	$1.16	$116,000.00	Disclosure SEC source: 0001373604-25-000084 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,649,432 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 28, 2025 Filed May 30, 2025 21:40 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	SaleCommon Stock	2,000,000	$1.16	$2,320,000.00	Disclosure SEC source: 0001373604-25-000084 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,749,432 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
May 28, 2025 Filed Jun 16, 2025 19:40 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	SaleCommon Stock	200,000	$1.09	$218,000.00	Disclosure SEC source: 0001373604-25-000090 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,017,432 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
April 23, 2025 Filed Apr 24, 2025 13:35 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	50,000	$2.98	$148,950.00	Disclosure SEC source: 0001373604-25-000065 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,800 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $2.979 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. Read SEC document
April 22, 2025 Filed Apr 24, 2025 13:35 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	300,000	$3.00	$900,000.00	Disclosure SEC source: 0001373604-25-000065 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 3,057,526 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
April 02, 2025 Filed Apr 2, 2025 22:07 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	15,209	$4.04	$61,407.86	Disclosure SEC source: 0001373604-25-000058 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P Disclosed balance after: 2,757,526 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.0376 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range F3 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
March 31, 2025 Filed Apr 2, 2025 22:07 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	19,566	$4.38	$85,667.77	Disclosure SEC source: 0001373604-25-000058 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 2,742,317 F1 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.3784 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. F3 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
March 27, 2025 Filed Mar 27, 2025 23:06 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	16,593	$5.19	$86,089.46	Disclosure SEC source: 0001373604-25-000056 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,800 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.1883 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range Read SEC document
March 27, 2025 Filed Apr 28, 2025 19:31 UTC Amendment	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	16,593	$5.19	$86,089.46	Disclosure SEC source: 0001373604-25-000069 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,800 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.1883 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range F4 · acquired: This amendment is being filed to correct BOX 4 on the transaction date of 3/27/25 to correct a clerical error. BOX 4 has been amended to "A", as the shares were acquired, not disposed. Read SEC document
March 27, 2025 Filed Apr 28, 2025 19:24 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	16,593	$5.19	$86,089.46	Disclosure SEC source: 0001373604-25-000067 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,800 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.1883 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range F4 · acquired: This amendment is being filed to correct BOX 4 on the transaction date of 3/27/25 to correct a clerical error. BOX 4 has been amended to "A", as the shares were acquired, not disposed. Read SEC document
March 26, 2025 Filed Mar 27, 2025 23:06 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	20,407	$5.04	$102,841.08	Disclosure SEC source: 0001373604-25-000056 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,207 F1 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.0395 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. Read SEC document
March 26, 2025 Filed Apr 28, 2025 19:31 UTC Amendment	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	20,407	$5.04	$102,841.08	Disclosure SEC source: 0001373604-25-000069 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,207 F1 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.0395 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. Read SEC document
March 26, 2025 Filed Apr 28, 2025 19:24 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	20,407	$5.04	$102,841.08	Disclosure SEC source: 0001373604-25-000067 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,207 F1 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.0395 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. Read SEC document
March 20, 2025 Filed Mar 21, 2025 00:02 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stovk	30,600	$5.61	$171,766.98	Disclosure SEC source: 0001373604-25-000051 · form4.xml · nonDerivative · entry 4 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,722,761 F4 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.6074 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. F3 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
March 19, 2025 Filed Mar 21, 2025 00:02 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	25,000	$4.94	$123,390.00	Disclosure SEC source: 0001373604-25-000051 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,692,161 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.9356per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range F3 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
March 18, 2025 Filed Mar 21, 2025 00:02 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	44,341	$4.73	$209,617.64	Disclosure SEC source: 0001373604-25-000051 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,667,161 F1 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.7274 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range. F3 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
March 18, 2025 Filed Mar 21, 2025 00:02 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	18,000	$4.60	$82,800.00	Disclosure SEC source: 0001373604-25-000051 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,622,820 F3 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
February 28, 2025 Filed Feb 28, 2025 21:04 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	85,068	$4.60	$391,015.06	Disclosure SEC source: 0001373604-25-000041 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,604,820 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.5965per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range F4 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
February 27, 2025 Filed Feb 28, 2025 21:04 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	86,802	$4.46	$387,093.52	Disclosure SEC source: 0001373604-25-000041 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,519,752 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.4595 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
February 26, 2025 Filed Feb 28, 2025 21:04 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	164,886	$4.01	$660,978.51	Disclosure SEC source: 0001373604-25-000041 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,432,950 F1 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.0087 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range F4 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 07, 2024 Filed Oct 9, 2024 15:25 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	OtherCommon Stock	102,076	Not disclosed	Not disclosed	Disclosure SEC source: 0001373604-24-000100 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · Former 10% owner of RPHM 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,076 F3 · price: Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). Read SEC document
October 07, 2024 Filed Oct 9, 2024 15:25 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	OtherCommon Stock	345,739	Not disclosed	Not disclosed	Disclosure SEC source: 0001373604-24-000100 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · Former 10% owner of RPHM 10b5-1 filing: No plan indicated Ownership: Indirect · Holdings of BML Investment Partners, L.P. Disclosed balance after: 345,739 F1 · price: Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). F2 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 25, 2024 Filed Sep 26, 2024 13:33 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	68,746	$1.50	$102,871.51	Disclosure SEC source: 0001373604-24-000098 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,457,395 F3 · price: Purchased in multiple transactions with a weighted average price of $1.4964. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 24, 2024 Filed Sep 26, 2024 13:33 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	29,600	$1.41	$41,866.24	Disclosure SEC source: 0001373604-24-000098 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,388,649 F2 · price: Purchased in multiple transactions with a weighted average price of $1.4144. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 18, 2024 Filed Sep 19, 2024 15:02 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	806	$1.40	$1,128.40	Disclosure SEC source: 0001373604-24-000094 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,359,049 F3 · price: Purchased in multiple transactions with a weighted average price of $1.40. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 17, 2024 Filed Sep 19, 2024 15:02 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	55,300	$1.36	$75,108.46	Disclosure SEC source: 0001373604-24-000094 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,358,243 F2 · price: Purchased in multiple transactions with a weighted average price of $1.3582. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 16, 2024 Filed Sep 16, 2024 20:15 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	172,747	$1.37	$236,870.69	Disclosure SEC source: 0001373604-24-000090 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,302,943 F4 · price: Purchased in multiple transactions with a weighted average price of $1.3712. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 13, 2024 Filed Sep 16, 2024 20:15 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	150,000	$1.31	$196,950.00	Disclosure SEC source: 0001373604-24-000090 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,130,196 F3 · price: Purchased in multiple transactions with a weighted average price of $1.313. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 12, 2024 Filed Sep 16, 2024 20:15 UTC	OnKure Therapeutics, Inc. RPHM · Entity 6550	PurchaseCommon Stock	36,176	$1.40	$50,523.40	Disclosure SEC source: 0001373604-24-000090 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,980,196 F2 · price: Purchased in multiple transactions with a weighted average price of $1.3966. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 06, 2024 Filed Sep 9, 2024 20:24 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	25,000	$1.48	$37,100.00	Disclosure SEC source: 0001373604-24-000088 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 248,702 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 05, 2024 Filed Sep 9, 2024 20:24 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	5,100	$1.40	$7,140.00	Disclosure SEC source: 0001373604-24-000088 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 223,702 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
September 03, 2024 Filed Sep 5, 2024 15:57 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	500	$4.00	$2,000.00	Disclosure SEC source: 0001373604-24-000086 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 218,602 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
August 30, 2024 Filed Sep 5, 2024 00:19 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	151	$4.25	$641.75	Disclosure SEC source: 0001373604-24-000084 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 218,602 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
August 28, 2024 Filed Aug 28, 2024 20:45 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	1,215	$3.96	$4,814.68	Disclosure SEC source: 0001373604-24-000081 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 217,951 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
August 26, 2024 Filed Aug 28, 2024 20:45 UTC	Talis Biomedical Corp TLIS · Entity 87664	PurchaseCommon Stock	13,167	$3.90	$51,322.33	Disclosure SEC source: 0001373604-24-000081 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 216,736 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
August 14, 2024 Filed Aug 15, 2024 00:24 UTC	AN2 Therapeutics, Inc. ANTX · Entity 1085	PurchaseCommon Stock	1,500,000	$1.04	$1,560,000.00	Disclosure SEC source: 0001373604-24-000066 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 5,749,432 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.